[go: up one dir, main page]

WO2006030219A3 - Methode de dosage biologique - Google Patents

Methode de dosage biologique Download PDF

Info

Publication number
WO2006030219A3
WO2006030219A3 PCT/GB2005/003561 GB2005003561W WO2006030219A3 WO 2006030219 A3 WO2006030219 A3 WO 2006030219A3 GB 2005003561 W GB2005003561 W GB 2005003561W WO 2006030219 A3 WO2006030219 A3 WO 2006030219A3
Authority
WO
WIPO (PCT)
Prior art keywords
sample
tse
results
prion protein
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/003561
Other languages
English (en)
Other versions
WO2006030219A8 (fr
WO2006030219A2 (fr
Inventor
Ginny Caroline Saunders
Verity Horigan
Anna Catherine Tout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Environment Food and Rural Affairs
Original Assignee
UK Secretary of State for Environment Food and Rural Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UK Secretary of State for Environment Food and Rural Affairs filed Critical UK Secretary of State for Environment Food and Rural Affairs
Publication of WO2006030219A2 publication Critical patent/WO2006030219A2/fr
Publication of WO2006030219A3 publication Critical patent/WO2006030219A3/fr
Publication of WO2006030219A8 publication Critical patent/WO2006030219A8/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une méthode visant à diagnostiquer la présence de l'absence d'une encéphalopathie spongiforme transmissible (EST) dans un échantillon, cette méthode consistant à: (i) soumettre l'échantillon à la digestion des protéases; (ii) détecter dans la digestion des protéases des substances résiduelles (a) une protéine prion (b) et une protéine endogène résistant aux protéases différente de la protéine prion résiduelle; et (iii) si les résultats de (b) sont positifs, utiliser les résultats de (a) pour déterminer si l'échantillon présente ou non une encéphalopathie spongiforme transmissible. Cette méthode est utilisée dans le diagnostic d'un éventail de maladies telles que l'ESB et la tremblante du mouton.
PCT/GB2005/003561 2004-09-16 2005-09-16 Methode de dosage biologique Ceased WO2006030219A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420566.2 2004-09-16
GB0420566A GB0420566D0 (en) 2004-09-16 2004-09-16 Assay method

Publications (3)

Publication Number Publication Date
WO2006030219A2 WO2006030219A2 (fr) 2006-03-23
WO2006030219A3 true WO2006030219A3 (fr) 2006-05-04
WO2006030219A8 WO2006030219A8 (fr) 2006-06-15

Family

ID=33306656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/003561 Ceased WO2006030219A2 (fr) 2004-09-16 2005-09-16 Methode de dosage biologique

Country Status (2)

Country Link
GB (1) GB0420566D0 (fr)
WO (1) WO2006030219A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002033420A2 (fr) * 2000-10-22 2002-04-25 Hadasit Medical Research Services And Development Ltd. Analyse d'urine servant a diagnostiquer des maladies a prion
US20020106324A1 (en) * 2000-01-20 2002-08-08 Jean Kadouche Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
WO2002082919A1 (fr) * 2001-04-17 2002-10-24 Femtolink Biotechnologies Llc Detection et quantification d'isoformes de prion dans des maladies neurodegeneratives par spectrometrie de masse

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106324A1 (en) * 2000-01-20 2002-08-08 Jean Kadouche Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
WO2002033420A2 (fr) * 2000-10-22 2002-04-25 Hadasit Medical Research Services And Development Ltd. Analyse d'urine servant a diagnostiquer des maladies a prion
WO2002082919A1 (fr) * 2001-04-17 2002-10-24 Femtolink Biotechnologies Llc Detection et quantification d'isoformes de prion dans des maladies neurodegeneratives par spectrometrie de masse

Also Published As

Publication number Publication date
WO2006030219A8 (fr) 2006-06-15
GB0420566D0 (en) 2004-10-20
WO2006030219A2 (fr) 2006-03-23

Similar Documents

Publication Publication Date Title
Juenemann et al. Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes
Raina et al. Abortive apoptosis in Alzheimer's disease
WO2006113915A3 (fr) Detection ultrasensible de prions par amplification cyclique automatique de mauvais repliements de proteines
Portelius et al. Identification of novel APP/Aβ isoforms in human cerebrospinal fluid
WO2010021822A3 (fr) Découverte de biomarqueurs candidats d’apoptose in vivo par profilage global de sites de coupure de caspase
WO2010019553A3 (fr) Procédé de détection de biomarqueurs et test d'état neurologique
MXPA03000226A (es) Diagnosticos tempranos de enfermedades conformacionales.
WO2005057166A3 (fr) Detection de proteines et de prions alteres de maniere conformationnelle
WO2003042659A3 (fr) Dosage biologique pour detecter rapidement la presence de prions
AR035956A1 (es) Deteccion y cuantificacion de isoformas de prion en enfermedades neurodegenerativas mediante espectrometria de masas.
WO2006086799A3 (fr) Reactifs de peptide specifiques au prion
Stoop et al. Decreased Neuro‐Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis
Heywood et al. The development of a peptide SRM-based tandem mass spectrometry assay for prenatal screening of Down syndrome
Cecarini et al. Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes
WO2006088823A3 (fr) Procede de detection de proteines et de prions a repliement incorrect
CA2364686A1 (fr) Test du prion
KR102728491B1 (ko) 전장 고분자량 키니노겐(hmwk) 및 절단된 hmwk를 구별하기 위한 펩타이드 정량화 검정법
WO2006030219A3 (fr) Methode de dosage biologique
BRPI0606529A2 (pt) método para a detecção da presença de um prìon patogênico em uma amostra e controle e substituto para uso em um ensaio de detecção de prìon
Vanessa et al. ALIX protein analysis: storage temperature may impair results
NZ526984A (en) Test for Transmissible Spongiform Encephalopathies
ATE530914T1 (de) Prionentest
WO2002033420A3 (fr) Analyse d'urine servant a diagnostiquer des maladies a prion
AU2003299390A8 (en) PrP detection method using an ancillary macrocyclic ligand
Kitauchi et al. Glycoprotein quality control-related proteins effectively inhibit fibrillation of amyloid beta 1–42

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 12/2006 UNDER (72, 75) THE ADDRESS SHOULD READ "TSE MOLECULAR BIOLOGY DEPARTMENT, VETERINARY LABORATORIES AGENCY, NEW HAW, ADDLESTONE, SURREY KT15 3NB, UNITED KINGDOM"

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase